Non-dietary therapeutic clinical trials in coeliac disease

European Journal of Internal Medicine

Volumn 23, Issue 1, 2012, Pages 9-14

  Crespo Pérez, Laura ^a   Castillejo De Villasante, Gemma ^b   Cano Ruiz, Ana ^a   León, Francisco ^c  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^c CENTOCOR INC   (United States)

Author keywords

Coeliac disease; Gluten free diet; Glutenases; Larazotide; Treatment

Indexed keywords

ALV 003; AN PEP; CCX 282B; GLUTEN; IMMUNOMODULATING AGENT; LARAZOTIDE; NEXVAX 2; PROTEINASE; TRAFICET EN; UNCLASSIFIED DRUG; VACCINE;

CELIAC DISEASE; CELL JUNCTION; CELL MEMBRANE PERMEABILITY; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DIETARY INTAKE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; ENZYME THERAPY; GASTROINTESTINAL SYMPTOM; GLUTEN FREE DIET; HEREDITY; HUMAN; IMMUNOMODULATION; LAMINA PROPRIA; NECATOR AMERICANUS; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE;

EID: 83555173695     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2011.08.030     Document Type: Short Survey

References (40)

1. A. Di Sabatino, and G.R. Corazza Coeliac disease Lancet 373 2009 1480 1493
2. R.F. Farrel, and C.P. Nelly Celiac sprue N Engl J Med 346 2002 180 188
3. P.H. Green, and C. Cellier Celiac disease N Engl J Med 357 2007 1731 1743
4. C. Mulder, and C. Cellier Coeliac disease Best Pract Res Clin Gastroenterol 19 2005 313 321
5. P.H. Green, and B. Jabri Coeliac disease Lancet 362 2003 383 391 (Pubitemid 36945070)
6. D. Schuppan, Y. Junker, and D. Barisani Celiac disease: from pathogenesis to novel therapies Gastroenterology 137 2009 1912 1933
7. F. Fernández-Bañares, M. Esteve-Comas, and M. Rosinach Screening of celiac disease in high risk groups Gastroenterol Hepatol 28 2005 561 566 (Pubitemid 41739947)
8. A. Fasano, I. Berti, T. Gerarduzzi, T. Not, R.B. Colleti, and S. Drago Prevalence of celiac disease in at risk and not-at-risk groups in the United States: a large multicenter study Arch Intern Med 63 2003 286 292 (Pubitemid 36183856)
9. M. Maki, K. Mustalahti, J. Kokkonen, P. Kulmala, M. Haapalahti, and T. Karttunen Prevalence of celiac disease among children in Finland N Engl J Med 348 2003 2517 2524 (Pubitemid 36706539)
10. S. Riestra, E. Fernández, and L. Rodrigo Prevalence of coeliac disease in the general population of Northern Spain. Strategies of serologic screening Scand J Gastroenterol 35 2000 398 402 (Pubitemid 30304423)
11. B. Fleckenstein, O. Molberg, S.W. Qiao, D.G. Schmid, and F. von der Mülbe Gliadin T cell epitope selection by tissue transglutaminase in celiac disease. Role of enzyme specificity and pH influence on the influence on the transamidation versus deamidation process J Biol Chem 277 2002 34109 34116
12. O. Molberg, S.N. Mcadam, R. Körner, H. Quarsten, C. Kristiansen, and L. Madsen Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease Nat Med 4 1998 713 717 (Pubitemid 28274673)
13. L. Shan, O. Molberg, I. Parrot, F. Hausch, F. Filiz, and G.M. Gray Structural basis for gluten intolerance in celiac disease Science 297 2002 2275 2279
14. Y. Van de Wal, Y. Kooy, P. Van Veelen, S. Peña, L. Mearin, and G. Papadopoulos Selective deamination by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity J Immunol 161 1998 1585 1588 (Pubitemid 28387571)
15. T. Matysiak-Budnik, C. Candalh, C. Dugave, A. Namane, C. Cellier, and N. Cerf-Bensussan Alterations of the intestinal transport and processing of gliadin peptides in celiac disease Gastroenterology 125 2003 696 707 (Pubitemid 37070688)
16. J.D. Schulzke, C.J. Bentzel, I. Schulzke, E.O. Riecken, and M. Fromm Epithelial tight junction structure in the jejunum of children with acute and treated celiac sprue Pediatr Res 43 1998 435 441 (Pubitemid 28157949)
17. L. Mauri, C. Ciacci, I. Ricciardelli, L. Vacca, V. Raia, and S. Auricchio Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease Lancet 362 2003 30 37 (Pubitemid 36835817)
18. R.W. DePaolo, V. Abadie, F. Tang, H. Fehlner-Peach, J.A. Hall, and W. Wang Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens Nature 471 2011 220 224
19. A. Castellanos-Rubio, I. Santin, I. Irastorza, L. Castaño, J. Carlos Vitoria, and J. Ramon Bilbao Th17 (and Th1) signatures of intestinal biopsies of CD patients in response to gliadin Autoimmunity 42 2009 69 73
20. S.K. Lee, W. Lo, L. Memeo, H. Rotterdam, and P.H. Green Duodenal histology in patients with celiac disease after treatment with a gluten-free diet Gastrointest Endosc 57 2003 187 191 (Pubitemid 36236757)
21. K. Holm, M. Maki, K. Vuolteenaho, K. Mustalahti, M. Ashorn, and T. Ruuska Oats in the treatment of childhood celiac disease: a 2 year controlled trial and a long term follow up study Aliment Pharmacol Ther 23 2006 1463 1472
22. C. Kupper Dietary guidelines and implementation for celiac disease Gastroenterology 128 2005 S124 S127
23. C. Catassi, E. Fabiani, G. Iacono, C. D'Agate, R. Francavilla, and F. Biagi A prospective, double blind, placebo controlled trial to establish a safe gluten threshold for patients with celiac disease Am J Clin Nutr 85 2007 160 166 (Pubitemid 46067630)
24. A. Lanzini, F. Lanzarotto, V. Villanacci, A. Mora, S. Bertolazzi, and D. Turini Complete recovery of intestinal mucosa occurs very rarely in adult celiac patients despite adherence to gluten-free diet Aliment Pharmacol Ther 29 2009 1299 1308
25. A.K. Akobeng, and A.G. Thomas Systematic review: tolerable amount of gluten for people with coeliac disease Aliment Pharmacol Ther 27 2008 1044 1052 (Pubitemid 351614885)
26. A. Gibert, M. Espadaler, A. Canela, A. Sánchez, C. Vaqué, and M. Rafecas Consumption of gluten-free products: should the threshold value for trace amounts of gluten be 20, 100 or 200 ppm? Eur J Gastroenterol Hepatol 18 2006 1187 1195 (Pubitemid 44563879)
27. B.M. Paterson, K.M. Lammers, M.C. Arrieta, A. Fasano, and J.B. Meddings The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study Aliment Pharmacol Ther 26 2007 757 766 (Pubitemid 47246202)
28. A. Fasano, S. Uzzau, C. Fiore, and K. Margaretten The enterotoxic effect on zonula occludens toxin on rabbit small intestine involves the paracellular pathway Gastroenterology 112 1997 839 846 (Pubitemid 27113809)
29. M. Marinaro, A. Fasano, and M.T. De Magistris Zonula occludens toxin acts as an adjuvant through different mucosal routes and induces protective immune responses Infect Immun 71 2003 1897 1902 (Pubitemid 36368721)
30. C.P. Kelly, P.H.R. Green, J.A. Murray, A. Di Marino, A. Colatrella, and D.A. Leffler Effect of larazotide acetate on the prevention of signs and symptoms of coeliac disease in patients undergoing a gluten challenge: a randomised placebo-controlled study Gastroenterology 136 2009 M2048
31. G.G. Pyle, B. Paaso, B.E. Anderson, D.D. Allen, T. Marti, and Q. Li Effect of pretreatment of food gluten with prolyl endopeptidase on gluten-induced malabsorption in celiac sprue Clin Gastroenterol Hepatol 3 2005 687 694 (Pubitemid 40984730)
32. J.A. Tye-Din, R.P. Anderson, R.A. Ffrench, G.J. Brown, P. Hodsman, and M. Siegel The effects of ALV003 pre-digestion of gluten on immune and symptoms in celiac disease in vivo Clin Immunol 134 2010 289 295
33. G.J. Tack, J. Van de water, E.M. Kooy-Winkelaar, J. van Bergen, G.A. Meijer, and B.M. von Blomberg Can prolyl-endoprotease enzyme treatment mitigate the toxic effect of gluten in coeliac patients? Gastroenterology 138 2010 S54
34. S.C. Donnelly, H.J. Ellis, and P.J. Ciclitira Pharmacological and management strategies for coeliac disease Expert Opin Pharmacother 12 2011 1731 1744
35. A.L. de Kauwe, Z. Chen, R.P. Anderson, C.L. Keech, J.D. Price, and O. Wijburg Resistance to celiac disease in humanized HLA-DR3-DQ2-transgenic mice expressing specific anti-gliadin CD4+ T cells J Immunol 182 2009 7440 7450
36. G.J. Brown, J. Daveson, J.K. Marjason, R.A. Ffrench, D. Smith, and M. Sullivan A phase i study to determine safety, tolerability and bioactivity of Nexvax2® in HLA DQ2+ volunteers with celiac disease following a long-term, strict gluten-free diet Gastroenterology 140 2011 S437 S438
37. H. Okada, C. Kuhn, H. Feillet, and J.F. Bach The 'hygiene hypothesis' for autoimmune and allergic diseases: an update Clin Exp Immunol 160 2010 1 9
38. A.J. Daveson, D.M. Jones, S. Gaze, H. McSorley, A. Clouston, and A. Pascoe Effect of hookworm infection on wheat challenge in celiac disease-a randomised double-blinded placebo controlled trial PLoS One 6 2011 e17366
39. L. Rodrigo Investigational therapies for celiac disease Expert Opin Investig Drugs 18 2009 1865 1873
40. L.M. Sollid, and C. Khosla Novel therapies for Coeliac Disease J Intern Med 296 2011 604 613